Bristol-Myers Pays $125 Million to Settle Plavix Securities Class Action

Bristol-Myers Squibb now has one less headache to worry about involving its Plavix blood-thinner product, one of the most prescribed medications in the world. In a Securities and Exchange Commission filing last week, the company revealed that in May, it agreed to pay $125 million to settle a securities class action that alleged BMS and its former chief executive violated securities laws by hiding material information about their efforts to settle a patent lawsuit with the Canadian generic drug maker Apotex Inc.